QR Code

B04 | OVERALL SURVIVAL AND DURATION OF TRANSFUSION INDEPENDENCE FOR FIRST-LINE ERYTHROPOIESIS STIMULATING AGENT-NAIVE PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH LUSPATERCEPT VS. EPOETIN ALFA: COMMANDS TRIAL

BACKGROUND: The phase 3 COMMANDS study (NCT03682536) showed that LUSPA improved red blood cell (RBC)-TI ≥12 wks with a concurrent hemoglobin increase of ≥1.5 g/dL in Wks 1 to 24 compared with EA and had durable clinical benefit in pts with ESA-naive TD LR-MDS. Here, we report updated OS and duratio...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: V. Santini, M. Della Porta, A. Zeidan, R.S. Komrokji, V. Pozharskaya, S. Rose, K. Keeperman, Y. Lai, S. Kalsekar, B. Aggarwal, D. Miteva, D. Valcárcel, P. Fenaux, J. Shortt, U. Platzbecker, G. Garcia-Manero
Format: Artigo
Langue:Inglês
Publié: Ferrata Storti Foundation 2025-09-01
Collection:Haematologica
Accès en ligne:https://haematologica.org/article/view/12856
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!